CBFB and acute myeloid leukemia: The annotated validation cohort (n=104) only contained AML samples and showed per class concordance scores of 0.83 for AML with t(v;11); KMT2A-r (n=47), 0.91 for AML with inv(16); t(16;16); CBFB::MYH11 (n=23), 1.00 for AML with mutated CEBPA (n=2), 1.00 for AML with t(6;9;DEK::NUP214 (n=1), 1.00 for AML with t(8;16); KAT6A::CREBBP (n=2), 1.00 for AML with t(8;21); RUNX1::RUNX1T1 (n=29) (Figure 2B, Supplementary Fig 1D).